Low-dose rituximab in steroid-refractory chronic graft-versus-host disease

Background: Chronic graft-versus-host disease (cGvHD) is a major complication that puts patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) at risk of death or infection. Currently, there is no gold standard for the first-line treatment of patients who do not respond to steroids, and there are several therapeutic options being evaluated in clinical trials for this disease to be used even in the first-line treatment for GvHD. There is evidence of the benefit of rituximab, an anti-CD20 antibody, at a standard dose of 375 mg/m2 weekly in the treatment of steroid-refractory chronic graft-versus disease (SR-cGvHD).Objective: To demonstrate the safety and efficacy of low-dose rituximab in a middle-income center in northeastern Mexico Study design: We report the experience of 26 patients with chronic graft-versus-graft disease who received low dose rituximab (100 mg weekly for 4 weeks). We utilized the advances in the National Institutes of Health (NIH) criteria for diagnosis, scoring, trial design, and assessment of treatment response.Results: We obtained a 5-year overall survival of 23.6%, including four patients with complete response. The 1 year event-free survival was 70% for patients with rituximab. During the treatment, there were 3 hospitalizations, and the causes were: immune thrombocytopenia, a parapneumonic effusion, and a cerebral vascular event. The median length of hospital stay was twelve days.Conclusion: A low dose of rituximab is an available and cost-effective option for patients with steroid-refractory cGvHD.

Automated summary

Low-dose rituximab is a safe and effective option for the treatment of steroid-refractory chronic graft-versus-host disease in middle-income regions.